Open Access. Powered by Scholars. Published by Universities.®

Medicine and Health Sciences Commons

Open Access. Powered by Scholars. Published by Universities.®

Edith Cowan University

2018

Inflammation

Articles 1 - 1 of 1

Full-Text Articles in Medicine and Health Sciences

Intense Exercise For Survival Among Men With Metastatic Castrate-Resistant Prostate Cancer (Interval-Gap4): A Multicentre, Randomised, Controlled Phase Iii Study Protocol, Robert Newton, Stacey A Kenfield, Nicolas H. Hart, June M Chan, Kerry S. Courneya, James Catto, Stephen P Finn, Rosemary Greenwood, Daniel C Hughes, Lorelei Mucci, Stephen R Plymate, Stephan F E Praet, Emer M Guinan, Erin L Van Blarigan, Orla Casey, Mark Buzza, Sam Gledhill, Li Zhang, Daniel A. Galvao, Charles J Ryan, Fred Saad May 2018

Intense Exercise For Survival Among Men With Metastatic Castrate-Resistant Prostate Cancer (Interval-Gap4): A Multicentre, Randomised, Controlled Phase Iii Study Protocol, Robert Newton, Stacey A Kenfield, Nicolas H. Hart, June M Chan, Kerry S. Courneya, James Catto, Stephen P Finn, Rosemary Greenwood, Daniel C Hughes, Lorelei Mucci, Stephen R Plymate, Stephan F E Praet, Emer M Guinan, Erin L Van Blarigan, Orla Casey, Mark Buzza, Sam Gledhill, Li Zhang, Daniel A. Galvao, Charles J Ryan, Fred Saad

Research outputs 2014 to 2021

INTRODUCTION: Preliminary evidence supports the beneficial role of physical activity on prostate cancer outcomes. This phase III randomised controlled trial (RCT) is designed to determine if supervised high-intensity aerobic and resistance exercise increases overall survival (OS) in patients with metastatic castrate-resistant prostate cancer (mCRPC).

METHODS AND ANALYSIS: Participants (n=866) must have histologically documented metastatic prostate cancer with evidence of progressive disease on androgen deprivation therapy (defined as mCRPC). Patients can be treatment-naïve for mCRPC or on first-line androgen receptor-targeted therapy for mCRPC (ie, abiraterone or enzalutamide) without evidence of progression at enrolment, and with no prior chemotherapy for mCRPC. Patients …